Johnson & Johnson Derivative Asset, Fair Value, Gross Liability
Johnson & Johnson (JNJ) had Derivative Asset, Fair Value, Gross Liability of $1.29 billion as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Offsetting › Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral
us-gaap:DerivativeAssetFairValueGrossLiability · last filed 2026-07-23
- 2026-06-28: Derivative Asset, Fair Value, Gross Liability $1.29B.
- 2026-03-29: Derivative Asset, Fair Value, Gross Liability $1.09B.
- 2025-12-28: Derivative Asset, Fair Value, Gross Liability $1.31B.
- 2025-09-28: Derivative Asset, Fair Value, Gross Liability $1.24B.
| Period end | Derivative Asset, Fair Value, Gross Liability |
|---|---|
| 2026-06-28 | $1.29B 10-Q · filed 2026-07-23 |
| 2026-03-29 | $1.09B 10-Q · filed 2026-04-22 |
| 2025-12-28 | $1.31B 10-Q · filed 2026-07-23 |
| 2025-09-28 | $1.24B 10-Q · filed 2025-10-22 |
| 2025-06-29 | $1.47B 10-Q · filed 2025-07-24 |
| 2025-03-30 | $1.70B 10-Q · filed 2025-04-23 |
| 2024-12-29 | $2.17B 10-K · filed 2026-02-11 |
| 2024-09-29 | $1.48B 10-Q · filed 2024-10-23 |
| 2024-06-30 | $1.91B 10-Q · filed 2024-07-25 |
| 2024-03-31 | $1.68B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.57B 10-K · filed 2025-02-13 |
| 2023-10-01 | $2.47B 10-Q · filed 2023-10-27 |
| 2023-07-02 | $2.12B 10-Q · filed 2023-07-31 |
| 2023-04-02 | $2.03B 10-Q · filed 2023-04-28 |
| 2023-01-01 | $2.18B 10-K · filed 2024-02-16 |
| 2022-10-02 | $4.44B 10-Q · filed 2022-10-27 |
| 2022-07-03 | $3.23B 10-Q · filed 2022-07-29 |
| 2022-04-03 | $1.66B 10-Q · filed 2022-04-29 |
| 2022-01-02 | $1.28B 10-K · filed 2023-02-16 |
| 2021-10-03 | $1.06B 10-Q · filed 2021-10-29 |
| 2021-07-04 | $833.00M 10-Q · filed 2021-07-29 |
| 2021-04-04 | $1.03B 10-Q · filed 2021-04-30 |
| 2021-01-03 | $1.11B 10-K · filed 2022-02-17 |
| 2020-09-27 | $1.12B 10-Q · filed 2020-10-23 |
| 2020-06-28 | $1.44B 10-Q · filed 2020-07-24 |
| 2020-03-29 | $2.53B 10-Q · filed 2020-04-29 |
| 2019-12-29 | $841.00M 10-K · filed 2021-02-22 |
| 2019-09-29 | $1.01B 10-Q · filed 2019-10-28 |
| 2019-06-30 | $437.00M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $592.00M 10-Q · filed 2019-05-01 |
| 2018-12-30 | $423.00M 10-K · filed 2020-02-18 |
| 2018-09-30 | $290.00M 10-Q · filed 2018-10-31 |
| 2018-07-01 | $295.00M 10-Q · filed 2018-08-02 |
| 2017-12-31 | $76.00M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |